8-K: Bioxytran Forms Joint Venture with Heme Foundation to Develop Universal Oxygen Carrier

Bioxytran has partnered with the Heme Foundation and NDPD Pharma to develop a Universal Oxygen Carrier (UOC) as a blood transfusion alternative, with the Heme Foundation initially contributing up to $10 million.

Summary

• Bioxytran, the Heme Foundation, and NDPD Pharma have formed a joint venture to develop a Universal Oxygen Carrier (UOC) for use in transfusion medicine and blood oxygenation therapy.
• The Heme Foundation will initially contribute up to $10 million for validation, while Bioxytran will provide expertise and intellectual property.
• NDPD Pharma will handle manufacturing, including developing a prototype, lyophilization process, and GMP compliant facility.
• The project is divided into six stages with a total estimated cost between $20 million and $25 million over 3.5 to 5 years.
• The UOC is designed to be compatible with all blood types, have an 18-hour half-life, and be shelf-stable for over 5 years without refrigeration.
• The joint venture has already invested over $2 million in prototypes and compound development.
• The UOC is intended to address the global blood shortage and provide a more accessible alternative to traditional blood transfusions.

Sentiment

Score: 8

Explanation: The document presents a promising joint venture with significant potential to address a critical healthcare need. The technology appears innovative, and the funding commitment is substantial. However, the project is still in early stages and faces risks, which tempers the overall sentiment.

Positives

• The UOC is designed to be compatible with all blood types, eliminating the need for blood type matching.
• The UOC has a long shelf life of 5+ years and does not require refrigeration, making it suitable for remote areas.
• The UOC has shown no known side effects in studies, unlike other hemoglobin-based oxygen carriers.
• The UOC has an 18-hour half-life, which is longer than some other blood substitutes.
• The Heme Foundation's $10 million initial investment provides significant funding for the project.
• The joint venture has already invested over $2 million in prototypes and compound development, showing progress.

Negatives

• The project is still in the early stages of development and requires significant further investment.
• The project is subject to several go/no-go decisions at the end of each stage, indicating potential for termination.
• The project is dependent on the successful completion of clinical trials and regulatory approvals.
• The term sheet is non-binding until definitive agreements are signed, creating some uncertainty.

Risks

• The project is subject to the successful completion of due diligence by all parties.
• The project is dependent on the successful completion of clinical trials and regulatory approvals.
• There is a risk of failure at any stage of the project, which would result in termination of the joint venture.
• The project is subject to customary closing conditions, including the absence of material adverse changes.
• The project is dependent on the Heme Foundation's continued funding.

Future Outlook

The joint venture aims to complete the development of the UOC, conduct clinical trials, and obtain regulatory approval for market launch. The project is divided into six stages with go/no-go decisions at the end of each stage.

Management Comments

• Leslie Ajayi, Chief Medical Officer of Bioxytran, Inc., stated that the UOC is a game-changing technology with applications beyond blood transfusions.
• Leslie Ajayi also noted that the UOC is equivalent to 18 hours of hyperbaric oxygen therapy in an intravenous shot without the side effects.

Industry Context

The development of a universal blood substitute addresses a critical need in the healthcare industry, particularly in areas with limited access to traditional blood transfusions. This project aligns with the broader trend of developing innovative solutions to address global health challenges.

Comparison to Industry Standards

• The document mentions that the first HBOC was discovered in the mid-1930s, indicating that the concept of blood substitutes is not new, but the UOC aims to overcome the side effects associated with previous HBOCs.
• Companies like Hemoglobin Oxygen Therapeutics LLC and KaloBios Pharmaceuticals have previously worked on HBOCs, but faced challenges with side effects and regulatory approvals.
• The UOC's shelf-stability and lack of refrigeration requirements are significant advantages compared to traditional blood products, which require strict storage conditions.
• The estimated development cost of $20-25 million is relatively high, but is in line with the costs associated with developing novel therapeutics.

Related Party Transactions

• NDPD Pharma, Inc. is an affiliate of Bioxytran, Inc., and the beneficial ownership includes the Company's officers.

Stakeholder Impact

• Shareholders may see potential long-term value from the development of the UOC.
• Employees of Bioxytran and NDPD will be involved in the development and manufacturing of the UOC.
• Customers, particularly hospitals and medical facilities, may benefit from a more accessible and reliable blood substitute.
• Suppliers of raw materials and equipment may see increased demand.
• Creditors may see increased financial stability for Bioxytran.

Next Steps

• The joint venture will proceed with the first stage of development, including hiring a project manager and locating a prototype development site.
• The joint venture will develop a carbohydrate molecule to be linked to the hemoglobin-based oxygen carrier.
• The joint venture will develop an initial manufacturing prototype.
• The joint venture will conduct small-scale animal trials for product validation.
• The joint venture will proceed with lyophilization of the compound and large-scale in-vivo testing in animals.
• The joint venture will submit a pre-IND application with the Indian Central Drugs Standard Control Organisation (CDSCO).
• The joint venture will develop GMP manufacturing and conduct human trials.

Key Dates

Keywords

Universal Oxygen Carrier, UOC, blood substitute, transfusion medicine, hemoglobin-based oxygen carrier, HBOC, joint venture, Heme Foundation, NDPD Pharma, blood oxygenation, clinical trials, lyophilization, GMP manufacturing